HUS year 2023: Operating revenue and operating costs

Operating revenue

Our operating revenue for 2023 came to EUR 2,906.5 million. Operating revenue fell short of the budget by 1.7%, or EUR 51.4 million.

The budget framework for fixed member billing totaled EUR 2,101.4 million, and we invoiced members accordingly. Actual use of services covered by the budget framework in 2023 exceeded the framework by EUR 34.6 million. We were unable to bill the difference because of the fixed funding scheme.

One of the main reasons for the shortfall in operating revenue was that we overestimated sales of coronavirus and sampling analytics in 2023.

Operating costs

Our operating costs totaled EUR 2,892.6 million. This exceeded the budget by 2.1%, or EUR 60.6 million.  

Personnel expenses

The principal cost item contributing to the budget excess was personnel costs, which exceeded the budget by 3.5%, or EUR 54 million. Personnel expenses totaled EUR 1,604.8 million. The level of salary increases in the health and social services sector for 2023 was not yet known at the time when the budget was drafted, and this resulted in an additional cost burden of c. EUR 48.5 million.

Purchased services

Purchases of services exceeded the budget by 1.4%, or EUR 8.6 million.  

Contributing factors to this excess included service voucher purchases and a larger than expected volume of outpatient care and inpatient care services purchased from other wellbeing services counties.

On the other hand, outside purchases of laboratory services fell short of the budget by 45.2%, or EUR 13.6 million, as the volume of coronavirus testing and sampling sold was lower than expected.  

Purchases of materials, supplies and pharmaceuticals

Purchases of materials and supplies were under budget by 1%, or EUR 5.6 million. This was mainly caused by the Diagnostic Center requiring less examination and medical supplies than expected.

Purchases of medications and pharmacy supplies exceeded the budget by 9%, or EUR 15.4 million, showing an increase of 1.6%, or EUR 3 million, on the previous year. Medication purchases exceeded expectations particularly in eye injections and cancer drugs. The increase in costs on the previous year was also affected by the fact that coronavirus medications ceased to be provided for free as of November 2023.

Other operating costs

Other operating costs exceeded the budget by 2.6%, or EUR 3.3 million, due to facility rental costs being higher than expected and due to credit losses. 

Depreciation and reductions in value

Depreciation and reductions in value exceeded the budget by 0.3%, or EUR 0.4 million, due to losses on sales of fixed assets.